FDA's MDMA Decision A Setback, Long-Term Outlook For Psychedelic Stocks Unchanged
The FDA has rejected MDMA therapy, but this setback could potentially benefit other psychedelic stocks.
Senior editor and writer for major media and tech organizations. Expert in the emerging psychedelic medicine industry. Contributor to National Geographic, Lonely Planet, and others.
As a former business owner and magazine founder, I understand the realities of producing content in a commercial world.
jnajum@gmail.com